Earnings Call · Q4 FY2022·2023-03-03

Q4 22EPS +4.62%·Rev n/aQ3 22EPS +7.94%·Rev n/aQ2 22EPS 0.00%·Rev n/aQ1 22EPS +7.35%·Rev n/a⚠ consensus missing

Syndax Pharmaceuticals Inc SNDX

Sharon Klahre — Head of Investor Relations

Michael Metzger — Chief Executive Officer

Dr. Briggs Morrison — Chief Medical Officer

Keith Goldan — Chief Financial Officer

−1.9%1d on move date−1.5% vs SPY3d−3.6%5d−4.4%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SNDX calls or request research access.

More SNDX calls Browse calls Request research access